Drugs / AGX-201
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02021474 | Oct 2022 → Jul 2023 | — | AgoneX Biopharmaceuticals, Inc. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AGX-201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02021474 ↗ |
| Route | Subcutaneous | “Subcutaneous injection” NCT02021474 ↗ |